



NOVEMBER 30 - DECEMBER 4 | 2020

ONLINE EVENT

5 days
with us

International Week on Surfactant Research

Clarifying the surfactant role in
neonates, children and adults with
respiratory failure



Organized by
Daniele De Luca (MD PhD), *France*

surfactantresearch.eu

NOVEMBER 30 - DECEMBER 4 | 2020

ONLINE EVENT
5 days with us
surfactantresearch.eu

International Week
on Surfactant Research



International Week on Surfactant Research

CHAIR

Daniele De Luca (*Paris, France*)

SCIENTIFIC COMMITTEE

Massimo Antonelli (*Roma, Italy*),

Giorgio Conti (*Roma, Italy*),

Pierre Tissieres (*Paris, France*),

Heide Flori (*Ann Arbor – MI, USA*),

David Tingay (*Melbourne, Australia*),

Anton van Kaam (*Amsterdam, Netherlands*),

Ram Ramanatham (*Los Angeles – CA, USA*),

Gerard Lambeau (*Nice, France*),

Salvatore M. Maggiore (*Pescara, Italy*)

ENDORSED BY



NOVEMBER 30 | 2020

- 13:30 - 14:00** **Greetings: Daniele De Luca (MD, PhD)**
- 14:00 - 16:00** **PRECLINICAL SESSION 1 – How can we enhance surfactant efficiency?**
Chairs: D. De Luca, L. Touqui (Paris, France)
- 14:00 - 14:15 The role of budesonide – *N. Hillman (St.Louis, MO – USA)*
 15min discussion
- 14:30 - 14:45 The role of varespladib and sPLA2 inhibitors – *G.Lambeau (Nice, France)*
 15min discussion
- 15:00 - 15:15 The role of DOPG – *MF. Krause (Kiel, Germany)*
 15min discussion
- 15:30 - 15:45 The role of hu-r-SP-D – *P. Kingma (Cincinnati, OH – USA)*
 15min discussion
- 16:00 - 17:00** **BREAK**
- 17:00 - 18:30** **CLINICAL SESSION 1 – How to study surfactant effect on the bedside in PICU/NICU?**
Chair: P.Rimensberger (Geneve, Switzerland)
- 17:00 - 17:15 EIT – *A. van Kaam (Amsterdam, Netherlands)*
 15min discussion
- 17:30 - 17:45 Lung ultrasound – *D. De Luca (Paris, France)*
 15min discussion
- 18:00 - 18:15 Lung MRI – *P. Kingma (Cincinnati, OH – USA)*
 15min discussion

DECEMBER 1 | 2020

- 14:00 - 16:30** **Clinical session 2 – Are there alternative way to deliver surfactant ?**
Chair: D. De Luca (Parigi, France)
- 14:00 - 14:15 Non-bronchoscopic bronchoalveolar lavage – *D. Tingay (Melbourne, Australia)*
🕒 15min discussion
- 14:30 - 14:45 Bronchoscopic broncho-alveolar lavage – *P. Biban (Verona, Italy)*
🕒 15min discussion
- 15:00 - 15:45 Supraglottic devices – *D. Trevisanuto (Padua, Italy)*
🕒 15min discussion
- 16:00 - 16:15 Nebulization – *F. Bianco (Parma, Italy)*
🕒 15min discussion
- 16:30 - 17:00** **BREAK**
- 17:00 - 19:00** **Preclinical Session 2 – Open questions in surfactant biology**
Chair: G. Lambeau (Nice, France)
- 17:00 - 17:20 What is the interaction between surfactant and secretory phospholipases?
D. Hite (Cincinnati, OH – USA)
🕒 10min discussion
- 17:30 - 17:50 What is the best animal model to study surfactant injury?
F. Salomone (Parma, Italy)
🕒 10min discussion
- 18:00 - 18:20 Can surfactant really be a drug carrier? – *J. Perez-Gil (Madrid, Spain)*
🕒 10min discussion
- 18:30 - 18:50 Can we distinguish between endogenous and exogenous surfactant metabolism?
VP. Carnielli (Ancona, Italy)
🕒 10min discussion

DECEMBER 2 | 2020

- 14:00 - 16:30** **Preclinical session 3 – What is what in surfactant biology?**
Chair: E. Lopez-Rodriguez (Hannover, Germany)
- 14:00 - 14:20 cPLA2 or sPLA2? What is the most important phospholipase in lung injury?
M. Murakami (Tokyo, Japan)
- 🕒 10min discussion
- 14:30 - 14:50 What is the effect of oxidative stress on surfactant? – *M. Vento (Valencia, Spain)*
- 🕒 10min discussion
- 15:00 - 15:20 What may be the best surfactant composition ? – *J. Perez-Gil (Madrid, Spain)*
- 🕒 10min discussion
- 16:00 - 16:20 What is the effect of hypothermia on surfactant ? – *D. De Luca (Paris, France)*
- 🕒 10min discussion
- 16:30 - 17:00** **BREAK**
- 17:00 - 18:30** **Clinical session 3 – Surfactant and ARDS**
Chair: MV. Ranieri (Bologna, Italy)
- 17:00 - 17:20 Epithelial and surfactant damage in various types of ARDS
C. Calfee (San Francisco, CA- USA)
- 🕒 10min discussion
- 17:30 - 17:50 Surfactant changes in ARDS and chronic lung injury – *A. Guenther (Giessen, Germany)*
- 🕒 10min discussion
- 18:00 - 18:20 Future directions for surfactant therapy in NARDS and PARDS
D. De Luca (Paris, France)
- 🕒 10min discussion

DECEMBER 3 | 2020

14:00 - 16:00 **Preclinical session 4 – Bedside biological test to evaluate surfactant status**
Chair: F. Salomone (Parma, Italy)

14:00 - 14:15 Spectroscopic lipid analysis – *H. Verder (Holbaek, Denmark)*

🕒 15min discussion

14:30 - 14:45 Surfactant adsorption test – *C. Autilio (Madrid, Spain)*

🕒 15min discussion

15:00 - 15:15 Lamellar body count – *D. De Luca (Paris, France)*

🕒 15min discussion

15:30 - 15:45 Stable microbubble test – *H. Fiori (Porto Alegre, Brasil)*

🕒 15min discussion

16:00 - 17:00 **BREAK**

17:00 - 19:00 **Clinical session 4 – ARDS: Surfactant system as biomarker**
Chair: M. Lewin (Corte Madera, CA - USA)

17:00 - 17:20 Phospholipases as biomarkers for ARDS – *M. Lekka (Ioannina, Greece)*

🕒 10min discussion

17:30 - 17:50 Surfactant proteins as biomarker for ARDS – *MD. Eisner (San Francisco, CA – USA)*

🕒 10min discussion

18:00 - 18:20 Surfactant proteins as biomarker for PARDS – *H. Flori (Ann Arbor, MI – USA)*

🕒 10min discussion

18:30 - 18:50 Biomarker for ARDS or biomarker for VILI in ARDS patients?
MV. Ranieri (Bologna, Italy)

🕒 10min discussion

DECEMBER 4 | 2020

- 14:00 - 15:30** **Clinical session 5 – Compassionate surfactant therapies in ARDS**
Chair: D. De Luca (Paris, France)
- 14:00 - 14:20 Use of surfactant therapies for NARDS – *D. Tingay (Melbourne, Australia)*
🕒 10min discussion
- 14:30 - 14:50 Use of surfactant therapies for PARDS – *M. Piastra (Rome, Italy)*
🕒 10min discussion
- 15:00 - 15:20 Use of surfactant for ARDS – *S. Busoni (Modena, Italy)*
🕒 10min discussion
- 15:30 - 16:30** **BREAK**
- 16:30 - 18:00** **Preclinical session 5 – Is there a role for surfactant in COVID19?**
Chair: M. Antonelli (Rome, Italy)
- 16:30 - 16:50 COVID19 is not (always) a “real” ARDS – *M. Cecconi (Milan, Italy)*
🕒 10min discussion
- 17:00 - 17:20 What really is respiratory failure due to COVID19? – *G. Iotti (Pavia, Italy)*
🕒 10min discussion
- 17:30 - 17:50 What really is COVID19 in PICU? – *P. Tissieres (Paris, France)*
🕒 10min discussion
- 18:00 - 18:10** **Closing remarks: Daniele De Luca (MD, PhD)**